Breast cancer adjuvant therapy: time to consider its time-dependent effects.
作者信息
Jatoi Ismail, Anderson William F, Jeong Jong-Hyeon, Redmond Carol K
机构信息
University of Texas Health Science Center, San Antonio, TX, USA.
出版信息
J Clin Oncol. 2011 Jun 10;29(17):2301-4. doi: 10.1200/JCO.2010.32.3550. Epub 2011 May 9.
Abstract
摘要
相似文献
1
Breast cancer adjuvant therapy: time to consider its time-dependent effects.乳腺癌辅助治疗：是时候考虑其时间依赖性效应了。
J Clin Oncol. 2011 Jun 10;29(17):2301-4. doi: 10.1200/JCO.2010.32.3550. Epub 2011 May 9.
2
Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.新辅助化疗前后Ki67表达在HR阴性乳腺癌中的预后价值
Int J Clin Exp Pathol. 2014 Sep 15;7(10):6862-70. eCollection 2014.
3
Can quantifying hormone receptor levels guide the choice of adjuvant endocrine therapy for breast cancer?量化激素受体水平能否指导乳腺癌辅助内分泌治疗的选择？
J Clin Oncol. 2011 Apr 20;29(12):1504-6. doi: 10.1200/JCO.2010.34.3202. Epub 2011 Mar 21.
4
Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers.雄激素受体表达是雌激素受体阳性乳腺癌的一个重要预后因素。
Breast Cancer Res Treat. 2010 Dec;124(3):607-17. doi: 10.1007/s10549-010-0761-y. Epub 2010 Feb 3.
6
CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients.CDO1 启动子甲基化是预测蒽环类药物治疗、雌激素受体阳性、淋巴结阳性乳腺癌患者预后的生物标志物。
BMC Cancer. 2010 Jun 1;10:247. doi: 10.1186/1471-2407-10-247.
7
Improved survival for women with stage I breast cancer in south-east Sweden: a comparison between two time periods before and after increased use of adjuvant systemic therapy.瑞典东南部I期乳腺癌女性患者生存率提高：辅助性全身治疗使用增加前后两个时间段的比较
Acta Oncol. 2009;48(4):504-13. doi: 10.1080/02841860902718754.
8
9
Adjuvant chemotherapy for lymph node-negative, estrogen receptor-negative breast cancer: a tale of three trials.淋巴结阴性、雌激素受体阴性乳腺癌的辅助化疗：三项试验的故事
J Natl Cancer Inst. 2004 Dec 15;96(24):1801-4. doi: 10.1093/jnci/djh347.
10
Efficacy of adjuvant chemotherapy according to Prion protein expression in patients with estrogen receptor-negative breast cancer.雌激素受体阴性乳腺癌患者中根据朊蛋白表达进行辅助化疗的疗效
Ann Oncol. 2007 Nov;18(11):1793-8. doi: 10.1093/annonc/mdm406. Epub 2007 Sep 14.
引用本文的文献
1
Ceramide-induced Endoplasmic Reticulum Stress as a Targetable Vulnerability in Endocrine Therapy-Resistant Breast Cancer.神经酰胺诱导的内质网应激作为内分泌治疗抵抗性乳腺癌的一个可靶向的脆弱点
bioRxiv. 2025 Aug 22:2025.08.18.670862. doi: 10.1101/2025.08.18.670862.
2
Molecular Subtypes and Ki-67 index in Breast Carcinoma with Special Emphasis on Triple Negative Breast Cancer. A 3-year Study in a Tertiary Care Center.乳腺癌的分子亚型与Ki-67指数，特别关注三阴性乳腺癌。在一家三级护理中心进行的为期3年的研究。
Indian J Surg Oncol. 2025 Apr;16(2):478-490. doi: 10.1007/s13193-023-01773-1. Epub 2023 May 30.
3
Retrospective analysis to validate the CTS5 in patients from El Álamo IV registry and GEICAM adjuvant studies.回顾性分析以验证来自埃尔阿拉莫IV注册研究和GEICAM辅助研究患者的CTS5。
Oncologist. 2025 Apr 4;30(4). doi: 10.1093/oncolo/oyaf040.
4
Calibration of transition probabilities to model survival of adjuvant trastuzumab for early breast cancer in Indonesia.校准转移概率以模拟印度尼西亚早期乳腺癌辅助曲妥珠单抗治疗的生存率。
Int J Technol Assess Health Care. 2025 Mar 26;41(1):e18. doi: 10.1017/S0266462325000157.
5
Pembrolizumab and chemotherapy in high-risk, early-stage, ER/HER2 breast cancer: a randomized phase 3 trial.帕博利珠单抗与化疗用于高危早期雌激素受体/人表皮生长因子受体2乳腺癌：一项随机3期试验
Nat Med. 2025 Feb;31(2):442-448. doi: 10.1038/s41591-024-03415-7. Epub 2025 Jan 21.
6
AI Survival Prediction Modeling: The Importance of Considering Treatments and Changes in Health Status over Time.人工智能生存预测建模：考虑治疗及健康状况随时间变化的重要性。
Cancers (Basel). 2024 Oct 18;16(20):3527. doi: 10.3390/cancers16203527.
7
Dynamic estimates of survival in patients with follicular thyroid cancer: a retrospective cohort study.滤泡性甲状腺癌患者生存情况的动态评估：一项回顾性队列研究。
Endocrine. 2025 Feb;87(2):627-634. doi: 10.1007/s12020-024-04010-z. Epub 2024 Sep 23.
8
Circulating Tumor DNA Is a Variant of Liquid Biopsy with Predictive and Prognostic Clinical Value in Breast Cancer Patients.循环肿瘤 DNA 是液体活检的一种变体，在乳腺癌患者的预测和预后中有临床价值。
Int J Mol Sci. 2023 Dec 2;24(23):17073. doi: 10.3390/ijms242317073.
9
Geriatric Breast Cancer: Staging, Molecular Surrogates, and Treatment. A Review & Meta-analysis.老年乳腺癌：分期、分子标志物和治疗。综述与荟萃分析。
Aging Dis. 2024 Aug 1;15(4):1602-1618. doi: 10.14336/AD.2023.1002.
10
Long-term prognostic value of the GenesWell BCT score in Asian women with hormone receptor-positive/HER2-negative early breast cancer.基因威 BCT 评分在亚洲激素受体阳性/HER2 阴性早期乳腺癌女性中的长期预后价值。
Breast Cancer. 2024 Jan;31(1):31-41. doi: 10.1007/s12282-023-01509-7. Epub 2023 Oct 9.
本文引用的文献
1
Improved endpoints for cancer immunotherapy trials.癌症免疫疗法试验的改善终点。
J Natl Cancer Inst. 2010 Sep 22;102(18):1388-97. doi: 10.1093/jnci/djq310. Epub 2010 Sep 8.
2
The hazards of endpoints.终点的风险。
J Natl Cancer Inst. 2010 Sep 22;102(18):1376-7. doi: 10.1093/jnci/djq334. Epub 2010 Sep 8.
3
Race/ethnicity and breast cancer estrogen receptor status: impact of class, missing data, and modeling assumptions.种族/民族与乳腺癌雌激素受体状态：阶层、缺失数据及建模假设的影响
Cancer Causes Control. 2008 Dec;19(10):1305-18. doi: 10.1007/s10552-008-9202-1. Epub 2008 Aug 14.
4
The evolution of treatment strategies: aiming at the target.治疗策略的演变：以目标为导向。
Breast. 2007 Dec;16 Suppl 2:S10-6. doi: 10.1016/j.breast.2007.07.032. Epub 2007 Aug 30.
5
Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?将基因表达谱分析应用于临床：分子特征何时会与患者护理相关？
Nat Rev Cancer. 2007 Jul;7(7):545-53. doi: 10.1038/nrc2173.
6
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series.在TRANSBIG多中心独立验证系列中，76基因预后特征对淋巴结阴性乳腺癌患者具有强烈的时间依赖性。
Clin Cancer Res. 2007 Jun 1;13(11):3207-14. doi: 10.1158/1078-0432.CCR-06-2765.
7
Commentary: the hazards of survival comparisons.评论：生存比较的危害
Oncologist. 2007 May;12(5):510-1. doi: 10.1634/theoncologist.12-5-510.
8
Approaches in modelling long-term survival: an application to breast cancer.长期生存建模方法：在乳腺癌中的应用
Stat Med. 2007 Jun 15;26(13):2666-85. doi: 10.1002/sim.2729.
9
Concordance among gene-expression-based predictors for breast cancer.基于基因表达的乳腺癌预测指标之间的一致性。
N Engl J Med. 2006 Aug 10;355(6):560-9. doi: 10.1056/NEJMoa052933.
10
Effects of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer.雌激素受体表达及组织病理学对乳腺癌年死亡率的影响。
Breast Cancer Res Treat. 2006 Nov;100(1):121-6. doi: 10.1007/s10549-006-9231-y. Epub 2006 May 10.
Zotero 插件